Equol Producers: Why Soy Affects People Differently
Haelan Publishing TeamShare
Two people eat the same bowl of miso soup. Inside their bodies, something different happens. One of them turns a soy compound called daidzein into a metabolite named equol; the other doesn't, and never has. It isn't willpower, and it isn't genetics in the way you'd expect — it comes down to which bacteria happen to live in the colon. It's one of the more fascinating wrinkles in soy science, and it explains a lot about why soy research can look so contradictory.
Key takeaways
Equol is a compound made by certain gut bacteria from daidzein, a soy isoflavone — not by the body itself. Only a portion of people carry the bacteria to do it: roughly 25–30% of adults in Western countries compared with about 50–60% in Asian countries, according to the Linus Pauling Institute. Because equol behaves differently from the daidzein it came from, researchers increasingly suspect that "equol producer status" is one reason soy studies produce such mixed results. What's still unsettled is whether you can change your status — and if so, how.
What is equol, exactly?
Soybeans contain a family of plant compounds called isoflavones. The two best known are genistein and daidzein. Daidzein is the interesting one here, because it isn't the end of the story — it's a starting material.
When daidzein reaches the colon, certain bacteria can chemically rework it into a different compound: equol. The Linus Pauling Institute describes equol as a metabolite with greater estrogenic activity than the daidzein it came from [1]. In other words, the bacteria don't simply break daidzein down — they convert it into something with a different biological character.
There's a further detail worth knowing. Equol comes in two mirror-image forms, and the version human gut bacteria make is specifically S-equol — described in the American Journal of Clinical Nutrition as the exclusive enantiomeric form produced by human intestinal bacterial flora, and a potent ligand for estrogen receptor beta [2]. So when you see "S-equol" on a research paper, that's why: it's the form your microbiome actually makes.
I like to think of it as a kitchen. Soy delivers the ingredients to the door. But whether anything gets cooked depends entirely on whether there's a cook in the kitchen — and not every kitchen has one.
What makes someone an equol producer?
The short answer: the bacteria you happen to be carrying.
Researchers have identified a handful of gut organisms capable of the conversion. A cross-sectional study of 1,044 Japanese adults published in Nutrients found two species — Asaccharobacter celatus and Slackia isoflavoniconvertens — were significantly more abundant and more prevalent in equol producers than non-producers [3]. Interestingly, those bacteria weren't entirely absent from non-producers; they were simply present at much lower levels.
Producer status also seems bound up with the broader health of the microbial community, not just one or two species. A prospective cohort study of 498 adults tracked over four years, published in BMC Microbiology, sorted participants into three groups: 30.9% stable producers, 26.1% unstable producers, and 43.0% non-producers [4]. The stable producers had noticeably greater overall bacterial diversity, and their microbiota were enriched in short-chain-fatty-acid-producing taxa — the same general cast of characters associated with a well-fed gut ecosystem.
That "unstable producer" category is a useful reality check. For a quarter of that cohort, equol production came and went across four years. It's less a fixed trait than a capacity that can flicker.
If the microbiome side of this interests you, we go deeper into it in our piece on fermented soy and your gut microbiome.
Why are equol producers more common in some parts of the world?
The geographic gap is striking, and it shows up consistently across studies — though the exact numbers vary depending on how researchers define and measure producer status.
| Population | Reported equol producers | Source |
|---|---|---|
| Adults in Western countries | ~25–30% | Linus Pauling Institute [1] |
| Adults in Asian countries | ~50–60% | Linus Pauling Institute [1] |
| Western adult vegetarians | ~50–60% | Linus Pauling Institute [1] |
| East Asian populations (2025 trial review) | 50–80% | Frontiers in Nutrition [5] |
| Western populations (2025 trial review) | 20–35% | Frontiers in Nutrition [5] |
The obvious hypothesis is diet, and the authors of that 2025 trial attribute the gap largely to lower dietary soy exposure in Western regions [5]. Notably, Western vegetarians — who typically eat more soy than the Western average — land closer to the Asian figures.
But it's worth being careful here. These are associations observed across populations, not proof that eating more soy creates the bacteria. Diet, early-life microbial exposure, fiber intake, antibiotic history and general gut ecology all travel together, and untangling them in observational data is genuinely hard.
A quick note before we go further: this article is for educational purposes only. It isn't medical advice, and none of it is meant to diagnose or treat anything. If you have questions about soy, hormone-sensitive conditions, or any medication you're taking, please talk with your healthcare professional — they know your situation in a way an article never can.
Why equol producer status complicates soy research
Here's where this stops being trivia and starts mattering. Imagine running a trial of soy isoflavones in a Western population where, say, 30% of participants are equol producers. If equol is doing meaningful biological work that daidzein alone doesn't do, then roughly two-thirds of your participants are receiving something chemically different from the other third — and you've averaged them all together. A real effect in a minority of participants could be diluted into statistical noise.
Researchers have started designing around this. The 2025 Frontiers in Nutrition pilot trial — a triple-blind, randomized, placebo-controlled study in 66 postmenopausal women — specifically analyzed outcomes by S-equol status, and reported that among equol producers, higher urinary S-equol concentrations were associated with greater improvement in skin measurements at day 42 [5].
The authors are refreshingly candid about the limits of that finding. It was a pilot study without a formal sample size calculation, so it may simply have been too small to detect meaningful effects reliably. There was no baseline stool sampling to identify equol-producing bacteria. And the participants had very low habitual soy intake, which limits how far the results generalize. It's a signal worth following, not a conclusion.
Still, the broader point stands: a study that ignores equol status may be measuring a blurred average of two different biological situations. That's a plausible partial explanation for why isolated-isoflavone trials have so often failed to reproduce what population studies of whole soy foods suggest — a tension we explore in soy isoflavone supplements vs. whole soy foods.
Can you become an equol producer?
This is the question everyone asks, and the honest answer is: nobody knows for certain.
There are reasons for optimism. The Nutrients study found daidzein intake was higher among producers, and the authors framed their findings around the idea that daidzein consumption is associated with producer status through increased abundance of the relevant bacteria [3]. The BMC Microbiology cohort found that stable production travels with greater microbial diversity [4] — and diversity is broadly associated with a varied, fiber-rich diet.
And there are reasons for caution. The Linus Pauling Institute notes plainly that prolonged soy consumption has not been shown to increase equol-producing ability [1]. The Nutrients authors themselves acknowledge their study was cross-sectional and observational, measured urine on a single day, and cannot establish that increased daidzein intake causes equol-producing capacity [3].
So: an association that makes biological sense, without the causal evidence to close the loop. If someone tells you confidently that eating more soy will turn you into an equol producer, they're ahead of the data.
Where fermented soy foods fit in
Fermentation changes soy before you ever eat it. Microbes at work in miso, tempeh, natto and other traditional fermented soy foods convert isoflavone glucosides — the sugar-bound forms — into aglycones, the sugar-free forms. The Linus Pauling Institute describes two distinct absorption peaks after eating soy: one from hydrolysis in the small intestine, and a second corresponding to aglycones absorbed after colonic bacteria act on the glycosides [1].
What that means for equol is less settled than you might hope. Fermentation shifts the chemistry of what arrives; it doesn't install the bacteria that make equol. The Linus Pauling Institute does note that certain fermented soy foods might influence microbiota composition — a "might" worth respecting as exactly that [1].
What we can say without stretching: traditional fermented soy foods deliver daidzein in a form your gut is already partway through processing, alongside the fiber and food matrix that come with eating whole foods rather than isolated compounds. If you're curious about how the fermented and unfermented versions differ, we've compared them side by side, and our piece on vitamin K2 covers another compound that fermentation — not the soybean — is responsible for creating.
Common questions
How do I know if I'm an equol producer?
Research studies determine it by measuring equol in urine or blood after a period of soy intake. There's no routine clinical test most people can order, and results can shift over time — a quarter of participants in one four-year cohort moved in and out of producer status [4]. For most people, it's an interesting research variable rather than something to act on.
Is equol a supplement I can just take?
S-equol supplements exist and are being studied. But the research picture is still developing, and taking an isolated metabolite is a different proposition from eating the whole food it derives from. As with any isoflavone-related product, people with hormone-sensitive conditions or taking medications such as tamoxifen or thyroid medication should talk with their clinician first.
Does being a non-producer mean soy is useless for me?
No. Daidzein and genistein are absorbed and biologically active in everyone, producer or not, and whole soy foods bring protein, fiber and other nutrients regardless of what happens to the daidzein. Equol is one pathway among several — an interesting one, not the whole story.
Do children produce equol?
Research suggests equol production is developmentally regulated and appears to relate to early diet, but the evidence base here is thinner than for adults. It's an active area of study rather than settled ground.
The bottom line
Equol is a good reminder that nutrition isn't just about what you eat — it's about what your resident microbes do with it. The same soy, the same daidzein, and two quite different metabolic outcomes depending on who's living in your colon.
It also argues for a certain humility about soy headlines. When a study says soy did or didn't do something, it's fair to ask whether anyone checked which participants were producing equol. Increasingly, researchers are. And it's one more reason the whole-food version of soy — with its full complement of compounds, fiber and food matrix — remains a more interesting proposition than any single isolated molecule.
Haelan 951 is a concentrated organic, non-GMO fermented soy beverage made with a proprietary nitrogen fermentation process. It's classified by the FDA as a food — not a supplement and not a drug — and it's made from whole soybeans rather than an isolated extract. For serving size and usage guidance, please refer to the product label.
References: [1] Soy Isoflavones — Linus Pauling Institute, Oregon State University [2] Setchell KDR et al. S-Equol, a potent ligand for estrogen receptor β, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. American Journal of Clinical Nutrition [3] Iino C et al. Daidzein Intake Is Associated with Equol Producing Status through an Increase in the Intestinal Bacteria Responsible for Equol Production. Nutrients, 2019 [4] Iino K et al. Stability of equol production capability is associated with the diversity of the gut microbiota of the host: a prospective cohort study. BMC Microbiology, 2026 [5] Vijayakumar S et al. S-equol status modulates skin response to soy isoflavones in postmenopausal women: a randomized placebo-controlled pilot trial. Frontiers in Nutrition, 2025
This content is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Always consult your healthcare professional before making changes to your diet or health routine.